EnteroBiotix Appoints David Lawrence to its Board of Directors

EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the Board appointment of David Lawrence as an independent Non-Executive Director. Mr. Lawrence is an accomplished executive with over 30 years of experience in finance, M&A, business development and corporate strategy in the life sciences industry.